Analysts Estimate Report : What to Look Out for Citius Pharmaceuticals Stock Forecast, Price & News (NASDAQ:CTXR)

0
228

Earnings results for Citius Pharmaceuticals Stock Forecast, Price & News (NASDAQ:CTXR)

Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingJun 2020 , the consensus EPS* forecast has remained the same over the past week at -0.11 and remained the same over the past month at -0.11. none raised and none lowered their forecast. For the fiscal year ending Sep 2020 , the consensus EPS* forecast has remained the same over the past week at -0.45 and remained the same over the past month at -0.45 . none raised and none lowered their forecast.

Citius Pharmaceuticals last posted its earnings data on May 14th, 2020. The reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.03. Citius Pharmaceuticals has generated $0.00 earnings per share over the last year. Citius Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, August 19th, 2020 based off prior year’s report dates.

Analyst Opinion on Citius Pharmaceuticals Stock Forecast, Price & News (NASDAQ:CTXR)

2 Wall Street analysts have issued ratings and price targets for Citius Pharmaceuticals in the last 12 months. Their average twelve-month price target is $5.50, predicting that the stock has a possible upside of 414.02%. The high price target for CTXR is $7.00 and the low price target for CTXR is $4.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Citius Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $5.50, Citius Pharmaceuticals has a forecasted upside of 414.0% from its current price of $1.07. Citius Pharmaceuticals has received no research coverage in the past 90 days.

Dividend Strength: Citius Pharmaceuticals Stock Forecast, Price & News (NASDAQ:CTXR)

Citius Pharmaceuticals does not currently pay a dividend. Citius Pharmaceuticals does not have a long track record of dividend growth.

Insiders buying/selling: Citius Pharmaceuticals Stock Forecast, Price & News (NASDAQ:CTXR)

In the past three months, Citius Pharmaceuticals insiders have not sold or bought any company stock. 56.84% of the stock of Citius Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. Only 4.73% of the stock of Citius Pharmaceuticals is held by institutions.

Earnings and Valuation of Citius Pharmaceuticals Stock Forecast, Price & News (NASDAQ:CTXR

Earnings for Citius Pharmaceuticals are expected to grow in the coming year, from ($0.45) to $0.72 per share. The P/E ratio of Citius Pharmaceuticals is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Citius Pharmaceuticals is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Citius Pharmaceuticals has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

More latest stories: here